坏疽性脓皮病治疗进展

Update of treatment of pyoderma gangrenosum

坏疽性脓皮病(PG)是一种以皮肤出现复发性、疼痛性及坏死性溃疡为特征的嗜中性皮病。目前尚无PG治疗的共识,且治疗困难。既往糖皮质激素为临床上常用的一线治疗药物,免疫抑制剂等其他传统药物可单独或联合糖皮质激素使用,但部分患者仍难以取得满意疗效。近年来生物制剂及小分子靶向药物逐渐应用于该病的治疗并取得了一定的疗效。本文主要对近年来治疗PG的生物制剂、JAK抑制剂等靶向药物的疗效和安全性进行综述,为临床治疗提供参考。

Pyoderma gangrenosum(PG)is a neutrophilic dermatosis characterized by recurrent,painful and necrotizing ulcers.There is neither consensus nor effective therapeutics on PG treatment at present,glucocorticoids were first-line treatment in clinical practice,immunosuppressants and other drugs can be used alone or in combination with glucocorticoids,but there's still difficulty achieving satisfactory results for some patients.Nowadays,biological agents and small molecule drugs have gradually applied to the treatment of PG and achieved certain effects.This review aims to summarize the efficacy and safety of targeted agents such as biological agents and JAK inhibitors to provide reference for clinical treatment.